TrialFrontiers in immunology2024

First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax).

Laura Ridolfi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.